Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07457918 | Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris) | PHASE3 | RECRUITING | 600 | — | — | Mar 11, 2026 | May 22, 2028 | May 5, 2026 | 4 | United States |
To assess the safety of YCANTH (VP-102/TO-208) by assessing adverse events (AEs), including expected local skin reactions (LSRs).
To assess the safety of YCANTH (VP-102/TO-208) by assessing the change from baseline body temperature.
To assess the safety of YCANTH (VP-102/TO-208) by assessing the change in baseline in vital signs (pulse).
To assess the safety of YCANTH (VP-102/TO-208) by assessing concomitant medication use.
To evaluate the efficacy of continued dermal application of YCANTH (VP-102/TO-208) when applied to each common wart once every 21 days for a maximum of 4 additional treatments. \*Baseline in the study will be either 1) Treatment Visit 1 (Day 1) of the parent study for subjects who received YCANTH (VP-102/TO-208) during the parent study; 2) the first Treatment Visit of this study for subjects who received Vehicle in the parent study; or 3) Treatment Visit 1 of the parent study for subjects who received Vehicle in the parent study and did not receive YCANTH (VP-102/TO-208) during this study.
| Arm | Type | Description |
|---|---|---|
| VP-102/TO-208 | EXPERIMENTAL | Combination Product: Cantharidin |
| Name | Type | Description |
|---|---|---|
| Cantharidin | COMBINATION_PRODUCT | A single-use applicator and applied in sufficient quantity to cover the entirety of each treatable common wart, including approximately a 1 to 2 mm margin of surrounding, healthy skin. The contents of no more than 2 applicators may be applied at each treatment visit. Each applicator contains 0.45 mL of 0.7% w/v cantharidin. Occlusive tape (occlusive tape with similar properties should be used across all clinical sites) will be applied to warts that have been treated. Once applied, the occlusive tape should be gently rubbed to maximize adherence to the treated area. |
Inclusion Criteria: Candidates will be included in the study if they: 1. Meet ≥ 1 of the following criteria: 1. Completed the Day 84 visit in the parent study and have ≥ 1 treatable common warts. 2. Completed the Day 105 visit in the parent study and have ≥ 1 treatable common warts. 3. C...